Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.50 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886339 | 0.96 | PLA2G2A (0.55) | PLA2G2AKMT2AMAPK8SERPINE1MDM2 | |
| SCHEMBL4887373 | 0.89 | SERPINE1 (0.55) | PLA2G2AKMT2AMAPK8SERPINE1KDM4E | |
| SCHEMBL5415705 | 0.88 | MAPK8 (0.52) | KMT2AMAPK8MDM2KDM4EMAPT | |
| SCHEMBL4893850 | 0.84 | PLA2G2A (0.46) | PLA2G2AKMT2AMDM2KDM4EMAPT | |
| SCHEMBL4884093 | 0.84 | AR (0.58) | PLA2G2AKMT2ASERPINE1MAPTLMNA | |
| SCHEMBL4893855 | 0.83 | HRH3 (0.48) | PLA2G2AKMT2AMDM2KDM4EMAPT | |
| SCHEMBL5173704 | 0.80 | KMT2A (0.50) | KMT2AMAPK8SERPINE1MDM2KDM4E | |
| SCHEMBL5172795 | 0.80 | KMT2A (0.50) | KMT2AMAPK8SERPINE1MDM2KDM4E | |
| SCHEMBL4893680 | 0.80 | AR (0.60) | PLA2G2AKMT2AKDM4EMAPTPKM | |
| SCHEMBL6858375 | 0.79 | KMT2A (0.47) | PLA2G2AKMT2AMAPK8SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319046-A1 | SUBSTITUTED SULFONAMIDE-INDOLES | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-7442805-B2 | Substituted sulfonamide-indoles | WYETH (US) | 2008-10-28 | — | — | US | disclosed |
| US-7332521-B2 | Substituted indoles | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070299126-A1 | Substituted pyrrole-indoles | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-7265148-B2 | Substituted pyrrole-indoles | WYETH (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1682530-B1 | PYRROLE SUBSTITUTED INDOLES AS INHIBITORS OF PAI-1 | WYETH CORP (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1682530-A1 | SUBSTITUTED PYRROLE-INDOLES AS INHIBITORS OF PAI-1 | Wyeth (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1667970-A1 | HETEROCYCLIC- OR ARYLOXY, -THIO 0R -AMINO SUBSTITUTED INDOLES-2-CARBOXYLIC ACIDS OR ESTERS AS PAI-1 INHIBITORS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1667969-A1 | SUBSTITUTED SULFONAMIDE-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS PAI-1 INHIBITORS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119327-A1 | Substituted indoles | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050113439-A1 | Substituted pyrrole-indoles | WYETH (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050096377-A1 | Substituted sulfonamide-indoles | WYETH (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005030756-A1 | SUBSTITUTED PYRROLE-INDOLES AS INHIBITORS OF PAI-1 | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030716-A1 | HETEROCYCLIC- OR ARYLOXY, -THIO OR -AMINO SUBSTITUTED INDOLES-2-CARBOXYLIC ACIDS OR ESTERS AS PAI-1 | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030715-A1 | SUBSTITUTED SULFONAMIDE-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS PAI-1 INHIBITORS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319046-A1 | SUBSTITUTED SULFONAMIDE-INDOLES | STS, TPST2, IDO2 | PLA2G2A 3606/4885KMT2A 172/4885MAPK8 3192/4885 |
| US-20050096377-A1 | Substituted sulfonamide-indoles | STS, TPST2, IDO2 | PLA2G2A 3606/4885KMT2A 172/4885MAPK8 3192/4885 |
| US-20050113439-A1 | Substituted pyrrole-indoles | IDO2, IDO1, TPH2 | PLA2G2A 3107/4885KMT2A 1959/4885MAPK8 4106/4885 |
| US-20070299126-A1 | Substituted pyrrole-indoles | IDO2, IDO1, TPH2 | PLA2G2A 3107/4885KMT2A 1959/4885MAPK8 4106/4885 |
| US-20050119327-A1 | Substituted indoles | IDO2, IDO1, TPH2 | PLA2G2A 3041/4885KMT2A 746/4885MAPK8 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.